Physician profile
Meera Menon
NPI 1427036888
$3,535.15
in general payments reported to CMS, 2019-2025
32 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $16.85 · 2021: $473 · 2022: $317 · 2023: $700 · 2024: $703 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $537.11 | 2019-2025 | Jardiance, Zepbound, Lyumjev |
| Sanofi-Aventis U.S. LLC | $500.62 | 2021-2025 | |
| Abbott Laboratories | $394.38 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Tandem Diabetes Care, INC. | $257.00 | 2019 | |
| Novo Nordisk INC | $208.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $196.92 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.78 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $138.57 | 2023-2025 | Evenity, Prolia, Prolia |
| Xeris Pharmaceuticals, INC. | $138.45 | 2021-2023 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $128.43 | 2021-2025 | Omnipod |
| Embecta Corp. | $115.30 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Dexcom, INC. | $95.23 | 2019-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $93.28 | 2022-2025 | |
| Corcept Therapeutics | $80.26 | 2025 | Korlym |
| Cequr Corporation | $66.58 | 2024-2025 | Cequr Simplicity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $51.05 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $47.60 | 2024-2025 | Yorvipath |
| Verity Pharmaceuticals INC. | $40.79 | 2024-2025 | Tlando |
| Recordati_rare_diseases_inc. | $39.58 | 2023-2024 | Signifor Lar, Isturisa |
| Amneal Pharmaceuticals LLC | $32.87 | 2024-2025 | Unithroid |
| Ascensia Diabetes Care US INC. | $31.33 | 2024 | |
| Madrigal Pharmaceuticals | $27.00 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals Lp | $25.86 | 2019-2021 | |
| Medtronic Minimed, INC. | $23.79 | 2019 | |
| Horizon Therapeutics Plc | $18.75 | 2023 | Tepezza |
| Lifescan, INC. | $17.89 | 2019 | |
| Nevro Corp. | $16.53 | 2023 | Senza |
| Echosens North America, INC. | $14.90 | 2025 | Fibroscan |
| Ibsa Pharma INC. | $14.64 | 2019 | |
| Becton, Dickinson and Company | $14.08 | 2019 | |
| Globus Medical, INC. | $13.92 | 2025 | Senza |
| Medtronic, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.